CurifyLabs secures $14M Series A to accelerate personalized medicine platform

CurifyLabs, a Helsinki-based health technology company, has closed a $14 million Series A funding round co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investor Lifeline Ventures. U.S. customers and employees also joined the round. The company will use the capital to expand U.S. operations, strengthen supply chain infrastructure, and accelerate development of its Compounding System Solution (CSS) platform, including the recently launched PharmaPrinter Aurum, which compounds medications up to nine times faster than manual processes. Founded in 2021, CurifyLabs targets hospital pharmacies and compounding centers with a hardware-software system that automates the production of personalized oral liquid medicines.

This funding sits at the intersection of pharmaceutical compounding and additive manufacturing, where the value proposition is not about part complexity but about dose accuracy, traceability, and on-demand production. CurifyLabs competes in a narrow but growing niche alongside companies like FabRx (UK) and Multiply Labs (US), though CurifyLabs differentiates by focusing on liquid formulations rather than solid-dose 3D printing. The medical-dental vertical has long been AM's most commercially mature segment, but personalized medicine remains a fragmented subsegment where regulatory clarity and reimbursement pathways are still evolving. CurifyLabs' approach - automating a manual, error-prone pharmacy process - addresses a real operational pain point, but the company must navigate pharmacy-level validation and hospital procurement cycles that are slower than typical medical device adoption.

For CurifyLabs, the practical challenge is execution: converting this capital into installed systems in U.S. hospital pharmacies, where regulatory acceptance and workflow integration will determine real adoption. The PharmaPrinter Aurum's speed advantage is meaningful only if it fits within existing compounding workflows and meets USP <795> standards for nonsterile preparations. The company's next milestone is not another product launch but referenceable deployments that demonstrate repeatable quality and cost savings over manual compounding.